鋸棕櫚 Saw Palmetto

INT-saw-palmetto-001 3 個適應症被研究

B 1 C 1 D 1

適應症與證據等級

雄性禿（雄性遺傳性禿髮） Androgenetic Alopecia

B 🟡 B 初步證據附警語發布 ⚠️ 中度市場風險

→

落髮（含雄性禿與休止期落髮） Hair Loss

C 🟠 C 薄弱證據已發布 ⚠️ 中度市場風險

→

良性攝護腺肥大 (BPH) Benign Prostatic Hyperplasia

D 🔴 D 反證據主流反證據 🚨 高市場風險

→

法規與權威立場 (L4)

L4a · US FDA

立場：cautious

Saw palmetto is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.

來源 ↗

L4b · EU EFSA

立場：neutral

1,548 claims on 'botanicals' have been placed on hold by the Commission pending further consideration on how to proceed with these

來源 ↗

L4c · UK NHS

立場：against

Your doctor should not offer you homeopathy, herbal treatments or acupuncture to treat urinary symptoms ... there is not enough reliable evidence about how well they work or how safe they are. ... [Saw palmetto] was no more effective than a placebo (an inactive substance) for BPH symptoms. No saw palmetto product has been conclusively shown to be effective for BPH.

來源 ↗

L4d · TW TFDA / 衛福部

立場：cautious

在台灣，鋸棕櫚這個成分目前還不能合法地加在食品裡面

來源 ↗

L4e · WHO

立場：neutral

WHO monographs on selected medicinal plants - Volume 2

來源 ↗

市場與行銷 (L10)

L10a · TW Market Channels

Swanson 鋸棕櫚 540mg

L10b · TW Legal Identity (TFDA)

尚未允許這類成分添加在食品裡

L10c · TW Community (PTT/Dcard/Mobile01)

口服確實有效但效果實在有限